Table 2.
Number of Patients With Hyperkalemic Events (n = 51) by Baseline Factors
| Variable | No. of Patients | No. of Events (%) | Event Rate per 100 Patient-Years (95% CI) |
|---|---|---|---|
| Baseline GFR, mL/min/1.73 m2 | |||
| ≤30 | 165 | 25 (15.2) | 6.87 (4.44–10.14) |
| >30 to ≤40 | 193 | 15 (7.8) | 2.75 (1.54–4.53) |
| >40 to ≤50 | 214 | 3 (1.4) | 0.45 (0.09–1.32) |
| >50 | 481 | 8 (1.7) | 0.52 (0.22–1.02) |
| Baseline BMI | |||
| ≤25 | 214 | 21 (9.8) | 3.53 (2.18–5.39) |
| >25 to ≤30 | 349 | 14 (4.0) | 1.33 (0.72–2.23) |
| >30 | 490 | 16 (3.3) | 1.09 (0.62–1.77) |
| Randomized drug | |||
| Ramipril | 417 | 30 (7.2) | 2.45 (1.65–3.50) |
| Metoprolol succinate | 428 | 17 (4.0) | 1.33 (0.77–2.13) |
| Amlodipine besylate | 208 | 4 (1.9) | 0.66 (0.18–1.68) |
| Baseline NSAID use | |||
| No | 938 | 45 (4.8) | 1.63 (1.19–2.19) |
| Yes | 115 | 6 (5.2) | 1.68 (0.61–3.65) |
| Baseline UP/Cr | |||
| ≤0.08 | 528 | 13 (2.5) | 0.77 (0.41–1.32) |
| >0.08–≤0.22 | 188 | 12 (6.4) | 2.19 (1.13–3.83) |
| >0.22–≤0.66 | 163 | 7 (4.3) | 1.51 (0.61–3.11) |
| >0.66 | 170 | 19 (11.2) | 4.66 (2.81–7.28) |
| Baseline potassium, mEq/L | |||
| <4 | 339 | 1 (0.3) | 0.10 (0.002–0.53) |
| 4–5 | 620 | 33 (5.3) | 1.83 (1.26–2.57) |
| >5 | 94 | 17 (18.1) | 6.56 (3.82–10.51) |
| Baseline glucose, mg/dL | |||
| <100 | 734 | 42 (5.7) | 1.98 (1.42–2.67) |
| 100–115 | 210 | 8 (3.8) | 1.24 (0.53–2.44) |
| >115 | 109 | 1 (0.9) | 0.29 (0.01–1.61) |
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CI, confidence interval; GFR, glomerular filtration rate; NSAID, nonsteroidal anti-inflammatory drug; UP/Cr, urinary protein to creatinine ratio.
SI conversion factors: To convert glucose to millimoles per liter, multiply by 0.0555; potassium to millimoles per liter, multiply by 1.0.